Cardiovascular death in rheumatoid arthritis: a population-based study
- PMID: 15751097
- DOI: 10.1002/art.20878
Cardiovascular death in rheumatoid arthritis: a population-based study
Abstract
Objective: To determine whether systemic inflammation confers any additional risk for cardiovascular death among patients with rheumatoid arthritis (RA), after adjusting for traditional cardiovascular risk factors and comorbidities.
Methods: Using the population-based data resources of the Rochester Epidemiology Project, we assembled an incidence cohort of all Rochester, Minnesota residents ages >or=18 years who first fulfilled the American College of Rheumatology 1987 criteria for RA between January 1, 1955 and January 1, 1995. All subjects were followed up longitudinally through their complete (inpatient, outpatient) medical records, beginning at age 18 years and continuing until death, migration, or January 1, 2001. Detailed information on the occurrence of various cardiovascular risk factors (personal history of coronary heart disease [CHD], congestive heart failure, smoking, hypertension, dyslipidemia, body mass index [BMI], diabetes mellitus, menopausal status) as well as indicators of systemic inflammation and RA disease severity (rheumatoid factor [RF] seropositivity, erythrocyte sedimentation rate [ESR], joint swelling, radiographic changes, RA nodules, RA complications, RA treatments, disease duration) and comorbidities were collected on all subjects. Causes of death were ascertained from death certificates and medical records. Cox regression models were used to estimate the independent predictors of cardiovascular death.
Results: This inception cohort comprised a total of 603 RA patients whose mean age was 58 years, of whom 73% were women. During a mean followup of 15 years, 354 patients died and cardiovascular disease was the primary cause of death in 176 patients. Personal history of CHD, smoking, hypertension, low BMI, and diabetes mellitus, as well as comorbidities, including peripheral vascular disease, cerebrovascular disease, chronic pulmonary disease, dementia, ulcers, malignancies, renal disease, liver disease, and history of alcoholism, were all significant risk factors for cardiovascular death (P < 0.01 for each). Multivariable Cox regression analyses, controlled for cardiovascular risk factors and comorbidities, revealed that the risk of cardiovascular death was significantly higher among RA patients with at least 3 ESR values of >or=60 mm/hour (hazard ratio [HR] 2.03, 95% confidence interval [95% CI] 1.45-2.83), RA vasculitis (HR 2.41, 95% CI 1.00-5.81), and RA lung disease (HR 2.32, 95% CI 1.11-4.84).
Conclusion: These results indicate that markers of systemic inflammation confer a statistically significant additional risk for cardiovascular death among patients with RA, even after controlling for traditional cardiovascular risk factors and comorbidities.
Similar articles
-
Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis.Arthritis Rheum. 2004 Nov;50(11):3450-7. doi: 10.1002/art.20612. Arthritis Rheum. 2004. PMID: 15529378
-
Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.Arthritis Rheum. 2005 Feb;52(2):402-11. doi: 10.1002/art.20853. Arthritis Rheum. 2005. PMID: 15693010 Review.
-
Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.J Rheumatol. 2006 Feb;33(2):248-55. Epub 2005 Dec 15. J Rheumatol. 2006. PMID: 16358365
-
The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years.Arthritis Rheum. 2005 Feb;52(2):412-20. doi: 10.1002/art.20855. Arthritis Rheum. 2005. PMID: 15692992
-
[Cardiovascular comorbidity in rheumatic disease. Does sex play a role?].Herz. 2005 Sep;30(6):512-21. doi: 10.1007/s00059-005-2717-2. Herz. 2005. PMID: 16170682 Review. German.
Cited by
-
Interstitial lung disease in rheumatoid arthritis in the era of biologics.Pulm Med. 2011;2011:931342. doi: 10.1155/2011/931342. Epub 2011 Dec 20. Pulm Med. 2011. PMID: 22229089 Free PMC article.
-
Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials.Arthritis Res Ther. 2020 Sep 9;22(1):206. doi: 10.1186/s13075-020-02229-5. Arthritis Res Ther. 2020. PMID: 32907617 Free PMC article. Clinical Trial.
-
Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity.Ther Adv Musculoskelet Dis. 2012 Jun;4(3):149-57. doi: 10.1177/1759720X11436239. Ther Adv Musculoskelet Dis. 2012. PMID: 22850632 Free PMC article.
-
Disease activity in rheumatoid arthritis and the risk of cardiovascular events.Arthritis Rheumatol. 2015 Jun;67(6):1449-55. doi: 10.1002/art.39098. Arthritis Rheumatol. 2015. PMID: 25776112 Free PMC article.
-
Prevention of stroke in rheumatoid arthritis.Curr Treat Options Neurol. 2015 Jul;17(7):356. doi: 10.1007/s11940-015-0356-3. Curr Treat Options Neurol. 2015. PMID: 25981388
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous